118 related articles for article (PubMed ID: 26650228)
1. Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class.
Gille H; Hülsmeyer M; Trentmann S; Matschiner G; Christian HJ; Meyer T; Amirkhosravi A; Audoly LP; Hohlbaum AM; Skerra A
Angiogenesis; 2016 Jan; 19(1):79-94. PubMed ID: 26650228
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
[TBL] [Abstract][Full Text] [Related]
3. First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.
Mross K; Richly H; Fischer R; Scharr D; Büchert M; Stern A; Gille H; Audoly LP; Scheulen ME
PLoS One; 2013; 8(12):e83232. PubMed ID: 24349470
[TBL] [Abstract][Full Text] [Related]
4. Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability.
Rodrigues GA; Mason M; Christie LA; Hansen C; Hernandez LM; Burke J; Luhrs KA; Hohman TC
Invest Ophthalmol Vis Sci; 2018 Dec; 59(15):5836-5846. PubMed ID: 30535424
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
6. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
Lowe J; Araujo J; Yang J; Reich M; Oldendorp A; Shiu V; Quarmby V; Lowman H; Lien S; Gaudreault J; Maia M
Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown.
Edelman JL; Lutz D; Castro MR
Exp Eye Res; 2005 Feb; 80(2):249-58. PubMed ID: 15670803
[TBL] [Abstract][Full Text] [Related]
10. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Wedge SR; Kendrew J; Hennequin LF; Valentine PJ; Barry ST; Brave SR; Smith NR; James NH; Dukes M; Curwen JO; Chester R; Jackson JA; Boffey SJ; Kilburn LL; Barnett S; Richmond GH; Wadsworth PF; Walker M; Bigley AL; Taylor ST; Cooper L; Beck S; Jürgensmeier JM; Ogilvie DJ
Cancer Res; 2005 May; 65(10):4389-400. PubMed ID: 15899831
[TBL] [Abstract][Full Text] [Related]
11. Anticalin
Rothe C; Skerra A
BioDrugs; 2018 Jun; 32(3):233-243. PubMed ID: 29748739
[TBL] [Abstract][Full Text] [Related]
12. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
14. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
[TBL] [Abstract][Full Text] [Related]
15. Development of a high affinity Anticalin
Deuschle FC; Morath V; Schiefner A; Brandt C; Ballke S; Reder S; Steiger K; Schwaiger M; Weber W; Skerra A
Theranostics; 2020; 10(5):2172-2187. PubMed ID: 32089738
[TBL] [Abstract][Full Text] [Related]
16. In vitro induction of protein complexes between bevacizumab, VEGF-A¹⁶⁵ and heparin: explanation for deposits observed on endothelial veins in monkey eyes.
Julien S; Biesemeier A; Schraermeyer U
Br J Ophthalmol; 2013 Apr; 97(4):511-7. PubMed ID: 23355530
[TBL] [Abstract][Full Text] [Related]
17. High-affinity VEGF antagonists by oligomerization of a minimal sequence VEGF-binding domain.
Stefano JE; Bird J; Kyazike J; Cheng AW; Boudanova E; Dwyer M; Hou L; Qiu H; Matthews G; O'Callaghan M; Pan CQ
Bioconjug Chem; 2012 Dec; 23(12):2354-64. PubMed ID: 23176598
[TBL] [Abstract][Full Text] [Related]
18. Interaction between bevacizumab and murine VEGF-A: a reassessment.
Yu L; Wu X; Cheng Z; Lee CV; LeCouter J; Campa C; Fuh G; Lowman H; Ferrara N
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):522-7. PubMed ID: 18234994
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
